Millennium Management LLC Sells 1,451,994 Shares of MaxCyte, Inc. (NASDAQ:MXCT)

Millennium Management LLC lessened its holdings in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 34.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 2,740,871 shares of the company's stock after selling 1,451,994 shares during the period. Millennium Management LLC owned approximately 2.59% of MaxCyte worth $11,402,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the business. Cadian Capital Management LP increased its stake in MaxCyte by 14.1% during the fourth quarter. Cadian Capital Management LP now owns 9,344,424 shares of the company's stock valued at $38,873,000 after acquiring an additional 1,155,476 shares during the period. Mirabella Financial Services LLP bought a new position in MaxCyte during the fourth quarter valued at about $15,392,000. River Global Investors LLP increased its stake in MaxCyte by 57.7% during the fourth quarter. River Global Investors LLP now owns 3,253,192 shares of the company's stock valued at $13,494,000 after acquiring an additional 1,190,630 shares during the period. Dimensional Fund Advisors LP increased its stake in MaxCyte by 15.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,429,071 shares of the company's stock valued at $5,945,000 after acquiring an additional 191,088 shares during the period. Finally, Chevy Chase Trust Holdings LLC increased its stake in MaxCyte by 0.6% during the fourth quarter. Chevy Chase Trust Holdings LLC now owns 1,339,829 shares of the company's stock valued at $5,574,000 after acquiring an additional 7,781 shares during the period. Institutional investors and hedge funds own 68.81% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on MXCT. BTIG Research set a $6.00 price target on MaxCyte and gave the company a "buy" rating in a research note on Wednesday, March 12th. Stifel Nicolaus lowered their price target on MaxCyte from $11.00 to $9.00 and set a "buy" rating on the stock in a research note on Wednesday, March 12th.

MaxCyte Stock Performance

Shares of MXCT stock traded down $0.01 during trading hours on Thursday, hitting $2.27. The company had a trading volume of 101,191 shares, compared to its average volume of 592,877. MaxCyte, Inc. has a 12 month low of $2.10 and a 12 month high of $5.26. The firm has a market capitalization of $240.81 million, a price-to-earnings ratio of -6.66 and a beta of 1.38. The firm's fifty day moving average is $2.56 and its 200 day moving average is $3.50.

MaxCyte (NASDAQ:MXCT - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.10) earnings per share for the quarter, meeting the consensus estimate of ($0.10). MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%. The company had revenue of $10.39 million for the quarter, compared to analyst estimates of $9.05 million. On average, sell-side analysts expect that MaxCyte, Inc. will post -0.42 EPS for the current fiscal year.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.